Minocycline Augmentation of Pharmacotherapy in Obsessive-Compulsive Disorder: An Open-Label Trial
Year: 2010
Type: article
Abstract: To the Editor: Most obsessive-compulsive disorder (OCD) patients treated with serotonin reuptake inhibitors (SRIs) show only partial reduction of symptoms.1 Data suggest that OCD may be caused in part by glutamatergic dysfunction in orbitofrontal/basal ganglia brain circuits, 2,3 and prior trials of glutamate modulators (eg, riluzole, memantine) given as augmentation to SRIs suggest that from 30% to 54% of OCD patients respond.[4][5][6][7][8] We conducted a 12-week, prospective, open-label study to assess whether SRI augmentation with minocycline, a tetracycline derivative with putative glutamate-modulating activity (ie, enhancing glial glutamate transport) 9 in addition to its antibiotic properties, would improve OCD symptoms.Advantages of minocycline include low cost (riluzole is expensive) and US Food and Drug Administration (FDA) approval in adults and children > 12 years (memantine is FDA approved only in adults).Minocycline is the most widely prescribed antibiotic for chronic acne because its antibiotic resistance is lower than those of other tetracyclines and antimicrobials.10 It has an excellent side
Authors: Carolyn I. Rodriguez, James Bender, Sue M. Marcus, Michael Snape, Moira Rynn, Helen Blair Simpson
Institutions: New York State Psychiatric Institute, Columbia University
Language: English
Subfield: Clinical Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: bronze
OpenAlex ID: W2037258739
